ICPT RSI Chart
Last 7 days
0.1%
Last 30 days
2.2%
Last 90 days
81.3%
Trailing 12 Months
27.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 294.5M | 306.5M | 317.7M | 0 |
2022 | 262.6M | 266.2M | 277.1M | 285.7M |
2021 | 297.3M | 288.3M | 275.4M | 260.8M |
2020 | 272.4M | 283.4M | 300.9M | 312.7M |
2019 | 196.1M | 218.8M | 233.8M | 252.0M |
2018 | 145.9M | 158.6M | 164.2M | 179.8M |
2017 | 45.6M | 70.9M | 107.1M | 131.0M |
2016 | 1.8M | 6.9M | 11.6M | 25.0M |
2015 | 2.8M | 2.8M | 2.8M | 2.8M |
2014 | 1.6M | 1.7M | 1.7M | 1.7M |
2013 | 2.1M | 1.7M | 1.6M | 1.6M |
2012 | 2.6M | 2.9M | 2.8M | 2.4M |
2011 | 0 | 0 | 0 | 1.8M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Nov 08, 2023 | miller-rich nancy | back to issuer | -154,109 | 19.00 | -8,111 | - |
Nov 08, 2023 | benatti luca | back to issuer | -154,109 | 19.00 | -8,111 | - |
Nov 08, 2023 | santini gino | back to issuer | -154,109 | 19.00 | -8,111 | - |
Nov 08, 2023 | ford david a | back to issuer | -406,600 | 19.00 | -21,400 | chief human resources officer |
Nov 08, 2023 | miller-rich nancy | sold | -423,776 | 19.00 | -22,304 | - |
Nov 08, 2023 | akkaraju srinivas | sold | -719,853 | 19.00 | -37,887 | - |
Nov 08, 2023 | saik andrew | back to issuer | -859,636 | 19.00 | -45,244 | evp & chief financial officer |
Nov 08, 2023 | venezia rocco | sold | -204,858 | 19.00 | -10,782 | chief accounting officer |
Nov 08, 2023 | akkaraju srinivas | back to issuer | -154,109 | 19.00 | -8,111 | - |
Nov 08, 2023 | venezia rocco | back to issuer | -278,711 | 19.00 | -14,669 | chief accounting officer |
Which funds bought or sold ICPT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 22, 2024 | MetLife Investment Management, LLC | sold off | -100 | -400,464 | - | -% |
Mar 11, 2024 | VANGUARD GROUP INC | sold off | -100 | -38,400,600 | - | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | sold off | -100 | -18,893,600 | - | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | sold off | -100 | -375,324 | - | -% |
Feb 26, 2024 | Virtu Financial LLC | sold off | -100 | -475,000 | - | -% |
Feb 20, 2024 | Quarry LP | sold off | -100 | -116,394 | - | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | sold off | -100 | -490,000 | - | -% |
Feb 15, 2024 | BARCLAYS PLC | sold off | -100 | -3,308,000 | - | -% |
Feb 15, 2024 | State of Wyoming | sold off | -100 | -59,569 | - | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -64,219 | - | -% |
Unveiling Intercept Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Intercept Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 46.8B | 6.8B | -7.84 | 6.83 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.1B | 2.0B | -57.6 | 9.55 | ||||
BMRN | 15.6B | 2.5B | 75.88 | 6.31 | ||||
INCY | 12.1B | 3.8B | 16.29 | 3.22 | ||||
MID-CAP | ||||||||
APLS | 5.9B | 396.6M | -11.13 | 14.84 | ||||
BBIO | 5.3B | 107.9M | -9.62 | 48.09 | ||||
AXSM | 3.6B | 251.0M | -12.17 | 14.37 | ||||
ARWR | 3.1B | 240.7M | -10.5 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.71 | 3.86 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.74 | 4.44 | ||||
NVAX | 666.2M | 983.7M | -1.22 | 0.68 | ||||
CRBP | 407.3M | 881.7K | -9.13 | 466.16 | ||||
INO | 277.6M | 4.9M | -2.05 | 57.05 | ||||
IBIO | 6.9M | 2.1M | -0.25 | 2.14 |
Intercept Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | 6.1% | 89.00 | 84.00 | 68.00 | 77.00 | 78.00 | 72.00 | 59.00 | 69.00 | 67.00 | 68.00 | 57.00 | 83.00 | 80.00 | 77.00 | 73.00 | 72.00 | 62.00 | 66.00 | 52.00 | 53.00 | 47.00 |
Cost Of Revenue | 6.5% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | -2.20 | 2.00 | 2.00 | 1.00 | 2.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Costs and Expenses | 2.8% | 93.00 | 91.00 | 100 | 95.00 | 88.00 | 85.00 | 86.00 | 90.00 | 86.00 | 82.00 | 111 | 44.00 | 135 | 129 | 156 | 161 | 137 | 130 | 136 | 135 | 105 |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 136 | 135 | 105 |
S&GA Expenses | -14.8% | 45.00 | 53.00 | 58.00 | 55.00 | 43.00 | 40.00 | 38.00 | 40.00 | 41.00 | 44.00 | 59.00 | -2.03 | 71.00 | 93.00 | 99.00 | 94.00 | 77.00 | 70.00 | 77.00 | 71.00 | 57.00 |
R&D Expenses | 11.3% | 42.00 | 37.00 | 42.00 | 40.00 | 44.00 | 45.00 | 48.00 | 50.00 | 45.00 | 38.00 | 51.00 | 49.00 | 49.00 | 34.00 | 57.00 | 65.00 | 60.00 | 60.00 | 58.00 | 63.00 | 48.00 |
Interest Expenses | -35.9% | 2.00 | 3.00 | 3.00 | 4.00 | 5.00 | 5.00 | 7.00 | 15.00 | 14.00 | 13.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 10.00 | 8.00 | 8.00 | 8.00 |
Net Income | 52.4% | -2.79 | -5.86 | -32.13 | -20.82 | 267 | -7.53 | -17.28 | -36.28 | -3.63 | -11.09 | -40.42 | -52.15 | -66.47 | -63.28 | -92.98 | -98.16 | -84.83 | -71.42 | -90.27 | -88.00 | -64.45 |
Net Income Margin | -128.5% | -0.19* | 0.68* | 0.70* | 0.78* | 0.74* | -0.24* | -0.26* | -0.35* | -0.39* | -0.59* | -0.75* | -0.88* | -1.07* | -1.20* | -1.28* | -1.37* | -1.43* | -1.44* | -1.62* | -1.72* | -2.02* |
Free Cashflow | 172.5% | 17.00 | -23.00 | -51.30 | -4.51 | -16.92 | 14.00 | -20.13 | 5.00 | 4.00 | 5.00 | -55.03 | -19.71 | -41.81 | -15.07 | -99.16 | -60.58 | -46.77 | -46.24 | -84.16 | -52.93 | -51.58 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Assets | -18.9% | 393 | 485 | 504 | 554 | 559 | 499 | 503 | 527 | 523 | 523 | 520 | 580 | 591 | 637 | 662 | 755 | 802 | 853 | 438 | 509 | 557 |
Current Assets | -18.5% | 383 | 471 | 490 | 540 | 545 | 487 | 477 | 508 | 496 | 493 | 488 | 546 | 561 | 607 | 628 | 721 | 769 | 819 | 403 | 482 | 529 |
Cash Equivalents | -24.6% | 103 | 136 | 61.00 | 51.00 | 113 | 58.00 | 48.00 | 85.00 | 68.00 | 146 | 93.00 | 58.00 | 45.00 | 51.00 | 41.00 | 70.00 | 63.00 | 94.00 | 55.00 | 43.00 | 59.00 |
Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.00 | 7.00 | 7.00 |
Net PPE | -9.3% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 3.00 | 3.00 | 4.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 6.00 | 7.00 | 7.00 | 10.00 | 11.00 |
Liabilities | -23.0% | 321 | 417 | 437 | 461 | 452 | 868 | 875 | 711 | 679 | 726 | 720 | 747 | 722 | 716 | 697 | 703 | 671 | 678 | 493 | 490 | 461 |
Current Liabilities | -51.4% | 91.00 | 187 | 207 | 230 | 222 | 151 | 151 | 168 | 144 | 145 | 146 | 179 | 163 | 164 | 150 | 162 | 140 | 125 | 108 | 114 | 88.00 |
Long Term Debt | 0.1% | 224 | 224 | 223 | 223 | 223 | 714 | 717 | 540 | 530 | 576 | 568 | 561 | 553 | 546 | 539 | 532 | 525 | 545 | 375 | 371 | 367 |
LT Debt, Non Current | 0.1% | 224 | 224 | 223 | 223 | 223 | 714 | 717 | 540 | 530 | 576 | 568 | 561 | 553 | 546 | 539 | 532 | 525 | 545 | 375 | 371 | 367 |
Shareholder's Equity | 6.4% | 72.00 | 68.00 | 67.00 | 93.00 | 108 | - | - | - | - | - | - | - | - | - | - | 52.00 | 131 | 175 | - | 19.00 | 96.00 |
Retained Earnings | -0.1% | -2,177 | -2,174 | -2,169 | -2,136 | -2,116 | -2,383 | -2,375 | -2,489 | -2,453 | -2,449 | -2,438 | -2,398 | -2,346 | -2,279 | -2,216 | -2,123 | -2,025 | -1,940 | -1,869 | -1,778 | -1,690 |
Additional Paid-In Capital | 0.3% | 2,257 | 2,250 | 2,244 | 2,238 | 2,232 | 2,016 | 2,008 | 2,309 | 2,300 | 2,249 | 2,241 | 2,234 | 2,218 | 2,202 | 2,186 | 2,176 | 2,157 | 2,116 | 1,815 | 1,800 | 1,788 |
Shares Outstanding | 0.1% | 42.00 | 42.00 | 42.00 | 42.00 | 31.00 | 30.00 | 30.00 | 30.00 | 32.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 32.00 | 31.00 | 31.00 | 30.00 | 28.00 | 28.00 |
Float | - | - | - | - | - | - | 335 | - | - | - | 555 | - | - | - | 1,259 | - | - | - | 2,028 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Cashflow From Operations | 171.6% | 16,686 | -23,302 | -51,597 | -4,806 | -16,588 | 14,738 | -20,124 | 5,175 | 3,562 | 4,847 | -54,650 | -17,813 | -40,478 | -14,842 | -98,731 | -60,484 | -46,756 | -45,948 | -83,425 | -52,812 | -51,581 |
Share Based Compensation | 6.2% | 6,653 | 6,262 | 5,864 | 5,231 | 5,788 | 5,489 | 5,381 | 7,151 | 7,188 | 5,274 | 8,419 | 4,805 | 15,825 | 16,083 | 12,473 | 13,173 | 13,130 | 14,782 | 14,897 | 11,499 | 11,994 |
Cashflow From Investing | -38.3% | 59,774 | 96,946 | 59,323 | -54,935 | 331,582 | -578 | -14,220 | 15,328 | -84,257 | 48,315 | 91,340 | 29,844 | 35,092 | 26,064 | 71,817 | 65,888 | 16,475 | -365,818 | 94,467 | 36,929 | 31,542 |
Cashflow From Financing | -255711.6% | -109,999 | -43.00 | -254 | -5,672 | -257,402 | -3,924 | -318 | -965 | 3,390 | -224 | -1,083 | -156 | -226 | 442 | -753 | 5,880 | 892 | 450,595 | 152 | 440 | 1,262 |
Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Condensed Consolidated Statements of Operations | ||||
Revenue | $ 88,789 | $ 77,588 | $ 240,465 | $ 208,491 |
Revenue, Product and Service [Extensible Enumeration] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember |
Operating expenses: | ||||
Cost of sales | $ 197 | $ 424 | $ 604 | $ 956 |
Selling, general and administrative | 45,438 | 43,274 | 156,441 | 121,013 |
Research and development | 41,513 | 44,034 | 120,530 | 136,753 |
Restructuring | 6,260 | 6,260 | ||
Total operating expenses | 93,408 | 87,732 | 283,835 | 258,722 |
Operating loss | (4,619) | (10,144) | (43,370) | (50,231) |
Other income (expense): | ||||
Interest expense | (1,802) | (5,237) | (7,423) | (18,579) |
Loss on extinguishment of debt | (91,759) | (91,739) | ||
Other income, net | 3,661 | 3,053 | 10,326 | 2,691 |
Total other income (expense), net | 1,859 | (93,943) | 2,903 | (107,627) |
Loss from continuing operations | (2,760) | (104,087) | (40,467) | (157,858) |
(Loss) income from discontinued operations, net of income taxes | (30) | 371,540 | (320) | 400,499 |
Net (loss) income | $ (2,790) | $ 267,453 | $ (40,787) | $ 242,641 |
Net income (loss) per common and potential common share (basic and diluted): | ||||
Net loss from continuing operations, Basic (in dollars per share) | $ (0.07) | $ (3.04) | $ (0.97) | $ (5.05) |
Net loss from continuing operations, Diluted (in dollars per share) | (0.07) | (3.04) | (0.97) | (5.05) |
Net (loss) income from discontinued operations, Basic (in dollars per share) | 0.00 | 10.83 | (0.01) | 12.81 |
Net (loss) income from discontinued operations, Diluted (in dollars per share) | 0.00 | 10.83 | (0.01) | 12.81 |
Net (loss) income, Basic (in dollars per share) | (0.07) | 7.80 | (0.98) | 7.76 |
Net (loss) income, Diluted (in dollars per share) | $ (0.07) | $ 7.80 | $ (0.98) | $ 7.76 |
Weighted average common and potential common shares outstanding: | ||||
Basic (in shares) | 41,792 | 34,293 | 41,731 | 31,262 |
Diluted (in shares) | 41,792 | 34,293 | 41,731 | 31,262 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 102,736 | $ 50,517 |
Restricted cash | 920 | 5,343 |
Investment debt securities, available-for-sale | 219,978 | 435,049 |
Accounts receivable, net of allowance for credit losses of $65 and $54, respectively | 32,479 | 26,862 |
Prepaid expenses and other current assets | 27,332 | 22,356 |
Total current assets | 383,445 | 540,127 |
Fixed assets, net | 822 | 987 |
Inventory | 2,649 | 6,462 |
Security deposits | 1,275 | 1,013 |
Other assets | 4,971 | 5,122 |
Total assets | 393,162 | 553,711 |
Current liabilities: | ||
Accounts payable, accrued expenses and other liabilities | 89,494 | 116,977 |
Short-term interest payable | 1,351 | 3,531 |
Current portion of long-term debt | 109,569 | |
Total current liabilities | 90,845 | 230,077 |
Long-term liabilities: | ||
Long-term debt | 223,856 | 223,104 |
Long-term other liabilities | 6,616 | 7,453 |
Total liabilities | 321,317 | 460,634 |
Commitments and contingencies (Note 15) | ||
Stockholders' equity: | ||
Common stock par value $0.001 per share; 90,000,000 shares authorized; 41,811,686 and 41,523,337 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | 42 | 42 |
Additional paid-in capital | 2,256,681 | 2,238,179 |
Accumulated other comprehensive loss, net | (7,203) | (8,256) |
Accumulated deficit | (2,177,675) | (2,136,888) |
Total stockholders' equity | 71,845 | 93,077 |
Total liabilities and stockholders' equity | $ 393,162 | $ 553,711 |